Euro
USD
British Pound
NULL
Product Description
Camrelizumab (AiRuiKa) is a humanized monoclonal IgG4 anti-PD-1 monoclonal antibody developed by Jiangsu Hengrui Medicine Co. Ltd for the treatment of various solid and hematological malignancies. Upon administration, the antibody blocks the binding of PD-1 to its ligands PD-L1 and PD-L2. This inhibits PD-1 downstream signaling and restores normal immune function by activating cytotoxic T lymphocytes and T cell-mediated immune responses against cancer cells. Currently, Camrelizumab is being investigated for treatment of advanced hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) and Hodgkin lymphoma
Biovision | A2132 | Anti-PD-1 (Camrelizumab), Humanized Antibody DataSheet
Antibody Target: PD-1
Target Alternative Name: PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l, AiRuiKa, SHR-1210, HR 301210, INCSHR 1210
Tag Line: Camrelizumab is a humanized IgG4 monoclonal antibody that blocks the binding of PD-1 to its ligands PD-L1 and PD-L2 and activates T-cell responses and inhibits the growth of cancer cells
Category: Primary antibody
Host: CHO cells
Isotype: Human IgG4
Species Reactivities:
Immunogen Sequence: Camrelizumab
Accession #:
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration:
Formulation: In PBS, pH 7.2
Purification:
Application: In vivo studies
Positive Control:
Application And Usages: In vivo studies
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
